Phase 3 Parkinson's Disease Trial, Active, Not Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been confirmed by lab testing to have epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
• People who have received 1 or 2 previous treatment regimens for ovarian cancer, including at least one treatment that contained platinum-based chemotherapy.
• People whose cancer has shown signs of growing or spreading on a scan within 6 months (180 days) after their last platinum-based chemotherapy — this is sometimes called platinum-resistant disease.
• People who are medically suitable to receive paclitaxel chemotherapy (and bevacizumab, if that treatment is being used).
• People with a good general level of physical functioning, rated 0 or 1 on a standard medical scale, assessed within 3 days before joining the trial (confirm with trial site).
• People who are not pregnant and not breastfeeding, and who either cannot become pregnant or are using a highly effective form of contraception (with a failure rate of less than 1% per year).
• People who have measurable or detectable disease visible on a scan, assessed by the local trial team.
• People who have provided a tumour tissue sample — either from stored tissue or a new biopsy from a site that has not previously been treated with radiation.
• People whose organs (such as kidneys, liver, and bone marrow) are functioning at an adequate level (confirm with trial site).
• People who have given written informed consent to take part in the study.

Who may not be able to join:

• People whose cancer is a non-epithelial type, or is classified as borderline, mucinous, seromucinous (predominantly mucinous), malignant Brenner's tumour, or undifferentiated carcinoma.
• People whose cancer grew or spread during, or within 28 days of finishing, their very first platinum-based chemotherapy — known as primary platinum-refractory disease.
• People whose cancer previously got worse while they were being treated with weekly paclitaxel on its own.
• People who have had more than 2 previous treatment regimens for ovarian cancer.
• People who received any systemic cancer treatment, investigational therapy, or maintenance therapy (including bevacizumab maintenance) within 4 weeks before joining the trial.
• People who received radiation therapy within 2 weeks before starting the trial treatment.
• People who have not fully recovered from surgery or surgical complications.
• People who received certain blood cell-stimulating medications (such as G-CSF or GM-CSF) within 4 weeks before joining the trial.
• People who received a live or live-attenuated vaccine within 30 days before the first dose of trial treatment.
• People who have received an experimental drug or used an experimental medical device within 4 weeks before starting the trial.
• People who have a diagnosed immune system deficiency or who are currently taking long-term steroid medication.
• People who have another cancer that is currently active or has required treatment within the past 3 years.
• People who have active cancer spread to the brain or the lining around the brain or spinal cord.
• People who have had a severe allergic reaction (Grade 3 or higher) to pembrolizumab, paclitaxel, bevacizumab, or any of their ingredients.
• People who have an active autoimmune disease that has needed systemic medical treatment within the past 2 years.
• People who have a history of, or currently have, non-infectious lung inflammation (pneumonitis or interstitial lung disease) that required steroid treatment.
• People who have an active infection currently requiring systemic treatment.
• People with a known history of HIV infection.
• People with a known history of Hepatitis B, or a currently active Hepatitis C infection.
• People with a medical condition, ongoing therapy, or other circumstance that could affect the reliability of the trial results (confirm with trial site).
• People with a known psychiatric condition or substance use disorder that could affect their ability to take part in the trial.
• People who, in the trial doctor's judgement, are unlikely to be able to follow the trial's procedures and requirements.
• People who have previously received a transplant of donor tissue or a solid organ.
• (For people being considered for bevacizumab specifically) People with uncontrolled high blood pressure.
• (For people being considered for bevacizumab specifically) People with a bowel blockage, abdominal fistula, gastrointestinal perforation, abdominal abscess, or evidence of cancer involving the lower bowel area on examination.
• (For people being considered for bevacizumab specifically) People with a history of blood clotting disorders, significant bleeding, coughing up blood, or active gastrointestinal bleeding within 6 months before joining the trial.

Important: Always verify eligibility with the trial site directly before applying.